



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Martin Bidlingmaier

✉ Martin.Bidlingmaier@med.uni-
muenchen.de

SPECIALTY SECTION

This article was submitted to
Pituitary Endocrinology,
a section of the journal
Frontiers in Endocrinology

RECEIVED 03 February 2023

ACCEPTED 06 February 2023

PUBLISHED 02 March 2023

CITATION

Bidlingmaier M, Biller BMK,
Clemmons D, Jørgensen JOL, Nishioka H
and Takahashi Y (2023) Corrigendum:
Guidance for the treatment of adult growth
hormone deficiency with somapacitan, a
long-acting growth hormone preparation.
Front. Endocrinol. 14:1158214.
doi: 10.3389/fendo.2023.1158214

COPYRIGHT

© 2023 Bidlingmaier, Biller, Clemmons,
Jørgensen, Nishioka and Takahashi. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Martin Bidlingmaier^{1*}, Beverly M.K. Biller², David Clemmons³,
Jens Otto L. Jørgensen⁴, Hiroshi Nishioka⁵
and Yutaka Takahashi^{6,7}

¹Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ²Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, ³Department of Medicine, University of North Carolina, Chapel Hill, NC, United States, ⁴Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan, ⁶Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan, ⁷Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

KEYWORDS

somapacitan, growth hormone, adult growth hormone deficiency, insulin-like growth factor I, treatment recommendations, pharmacokinetic/pharmacodynamic modelling, long-acting growth hormone

A Corrigendum on

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.

by Bidlingmaier M, Biller BMK, Clemmons D, Jørgensen JOL, Nishioka H and Takahashi Y (2022) *Front. Endocrinol.* 13:1040046. doi: 10.3389/fendo.2022.1040046.

Incorrect copyright statement

In the published article, there was an error in the Copyright statement of [Figure 1](#). The statement was incorrectly written as “Reproduced with permission (24).”. The corrected statement is “Reproduced from Bentz Damholt et al. (24) under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>). No changes were made to this figure.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1
 Simulated weekly IGF-I SDS levels following dosing with somapacitan (weekly GH [mean dose 2.4 mg]) and somatropin (daily GH [mean dose 0.3 mg]). Dashed line is weekly average IGF-I SDS for somapacitan (-0.09 SDS). Reproduced from Bentz Damholt et al. (24) under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the

reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.